Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03390686 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | active not recruiting | Phase 3 | 650 | Prestige Biopharma LimitedINDUSTRY | 17 | May 31, 2025 | clinicaltrials |
| NCT06598527 | Stereotactic Body Radiotherapy Followed by Tislelizumab Plus Platinum-based Chemotherapy Versus Tislelizumab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Stage Ⅱ-Ⅲ Non-small Cell Lung Cancer: A Phase Ⅲ, Randomized, Multicenter, Prospective Study(SACTION2401) | recruiting | Phase 3 | 360 | Yang Hong |
| 1 |
| May 29, 2025 |
| clinicaltrials |
| NCT04774380 | Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer(LUMINANCE) | completed | Phase 3 | 152 | AstraZenecaINDUSTRY | 6 | May 23, 2025 | clinicaltrials |
| NCT06970782 | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure(KYLIN-3) | not yet recruiting | Phase 3 | 278 | Avistone Biotechnology Co., Ltd.INDUSTRY | 0 | May 21, 2025 | clinicaltrials |
| NCT06082635 | TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 321 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT04427072 | Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation(GeoMETry-III) | terminated | Phase 3 | 22 | Novartis PharmaceuticalsINDUSTRY | 18 | May 16, 2025 | clinicaltrials |
| NCT06968221 | Bovine Reinforcement in Stomach, Colorectal and Lung Operation | recruiting | Phase 3 | 172 | Shanghai Cingularbio Co. LtdINDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06961201 | Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase | not yet recruiting | Phase 3 | 94 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT06955325 | Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations(UPLIFT) | not yet recruiting | Phase 3 | 270 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | May 6, 2025 | clinicaltrials |
| NCT01853826 | An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s) | completed | Phase 3 | 481 | Boehringer IngelheimINDUSTRY | 11 | Apr 11, 2025 | clinicaltrials |
| NCT03631706 | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 304 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 18 | Apr 8, 2025 | clinicaltrials |
| NCT06829459 | A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | recruiting | Phase 3 | 350 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT01394679 | A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung Cancer | not yet recruiting | Phase 3 | 154 | Cell>Point LLCINDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04786964 | Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC(CONTERNO) | terminated | Phase 3 | 25 | Checkpoint Therapeutics, Inc.INDUSTRY | 8 | Apr 2, 2025 | clinicaltrials |
| NCT05255302 | De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction(DIAL) | recruiting | Phase 2 / Phase 3 | 1,360 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT03676192 | To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 689 | CelltrionINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04316013 | Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial | terminated | Phase 3 | 254 | Peter MacCallum Cancer Centre, AustraliaOTHER | 3 | Mar 14, 2025 | clinicaltrials |
| NCT06617416 | A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC | recruiting | Phase 3 | 560 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT00446225 | Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR(EURTAC) | completed | Phase 3 | 174 | Spanish Lung Cancer GroupOTHER | 3 | Mar 5, 2025 | clinicaltrials |
| NCT06858410 | Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma | not yet recruiting | Phase 3 | 36 | Guangdong Association of Clinical TrialsOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT04005716 | Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 457 | BeiGeneINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06847334 | A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | not yet recruiting | Phase 3 | 772 | Shanghai Henlius BiotechINDUSTRY | 0 | Feb 26, 2025 | clinicaltrials |
| NCT03088813 | Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer(RESILIENT) | completed | Phase 3 | 491 | IpsenINDUSTRY | 18 | Feb 19, 2025 | clinicaltrials |
| NCT06828757 | Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 94 | Hunan Province Tumor HospitalOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT02231164 | LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research | terminated | Phase 3 | 12 | Boehringer IngelheimINDUSTRY | 3 | Feb 13, 2025 | clinicaltrials |
| NCT06789796 | a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy. | not yet recruiting | Phase 3 | 636 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 11, 2025 | clinicaltrials |
| NCT03358875 | Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)(RATIONALE-303) | completed | Phase 3 | 805 | BeiGeneINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT01828112 | LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | completed | Phase 3 | 231 | Novartis PharmaceuticalsINDUSTRY | 20 | Feb 7, 2025 | clinicaltrials |
| NCT02349412 | Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers | completed | Phase 3 | 405 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03663205 | A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer | completed | Phase 3 | 334 | BeiGeneINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT02887521 | Pulmonary Rehabilitation Before Lung Cancer Resection | terminated | Phase 3 | 9 | Alliance for Clinical Trials in OncologyOTHER | 2 | Feb 3, 2025 | clinicaltrials |
| NCT02576574 | Avelumab in First-line NSCLC (JAVELIN Lung 100) | completed | Phase 3 | 1,214 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 42 | Jan 31, 2025 | clinicaltrials |
| NCT04597671 | Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)(NVALT28) | active not recruiting | Phase 3 | 170 | Association NVALT StudiesOTHER | 1 | Jan 29, 2025 | clinicaltrials |
| NCT01828099 | LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | completed | Phase 3 | 376 | Novartis PharmaceuticalsINDUSTRY | 29 | Jan 16, 2025 | clinicaltrials |
| NCT04012606 | Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 3 | 442 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06759857 | FHND9041 Versus Afatinib for Non-small Cell Lung Cancer(FHND9041) | enrolling by invitation | Phase 3 | 350 | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT00418886 | Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients(ZEAL) | completed | Phase 3 | 698 | Genzyme, a Sanofi CompanyINDUSTRY | 21 | Dec 31, 2024 | clinicaltrials |
| NCT05922345 | Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. | unknown | Phase 3 | 518 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT02754882 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 763 | Samsung Bioepis Co., Ltd.INDUSTRY | 13 | Dec 16, 2024 | clinicaltrials |
| NCT06704620 | Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 430 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT00478699 | Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)(GECP-SCAT) | completed | Phase 3 | 500 | Spanish Lung Cancer GroupOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | recruiting | Phase 3 | 180 | Luye Pharma Group Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02588261 | A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations(SOLAR) | terminated | Phase 3 | 530 | Astellas Pharma Global Development, Inc.INDUSTRY | 23 | Dec 10, 2024 | clinicaltrials |
| NCT04830813 | Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer | completed | Phase 3 | 184 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06719336 | Addition of Thoracic Consolidation Radiotherapy to the Maintenance Immunotherapy for ES-SCLC (STONE-001) | not yet recruiting | Phase 3 | 182 | Anhui Shi, MDOTHER | 0 | Dec 5, 2024 | clinicaltrials |
| NCT04956692 | Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | active not recruiting | Phase 3 | 531 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Dec 3, 2024 | clinicaltrials |
| NCT04923906 | Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations | active not recruiting | Phase 3 | 624 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
Data updated 24 days agoSource updated May 31, 2025source: clinicaltrials